These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15741499)

  • 1. Neurotensin receptor agonists and antagonists for schizophrenia.
    Richelson E; Fredrickson PA; Boules MM
    Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotensin receptor agonists and antagonists for schizophrenia.
    Robertson VB; Wilson MS
    Am J Psychiatry; 2005 Mar; 162(3):634; author reply 635. PubMed ID: 15741502
    [No Abstract]   [Full Text] [Related]  

  • 3. Neurotensin agonists as an alternative to antipsychotics.
    Boules M; Fredrickson P; Richelson E
    Expert Opin Investig Drugs; 2005 Apr; 14(4):359-69. PubMed ID: 15882113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatments of schizophrenia: targeting the neurotensin system.
    Kinkead B; Nemeroff CB
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):205-18. PubMed ID: 16611093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotensin analogs indications for use as potential antipsychotic compounds.
    McMahon BM; Boules M; Warrington L; Richelson E
    Life Sci; 2002 Jan; 70(10):1101-19. PubMed ID: 11848295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.
    Keiser AA; Matazel KS; Esser MK; Feifel D; Prus AJ
    Exp Clin Psychopharmacol; 2014 Dec; 22(6):541-7. PubMed ID: 25222546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioactive analogs of neurotensin: focus on CNS effects.
    Boules M; Fredrickson P; Richelson E
    Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.
    Richelson E; Boules M; Fredrickson P
    Life Sci; 2003 Jun; 73(6):679-90. PubMed ID: 12801589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
    Cáceda R; Kinkead B; Nemeroff CB
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
    Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA
    Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
    Mesnage V; Houeto JL; Bonnet AM; Clavier I; Arnulf I; Cattelin F; Le Fur G; Damier P; Welter ML; Agid Y
    Clin Neuropharmacol; 2004; 27(3):108-10. PubMed ID: 15190231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion.
    Norman C; Beckett SR; Spicer CH; Ashton D; Langlois X; Bennett GW
    J Psychopharmacol; 2008 May; 22(3):300-7. PubMed ID: 18208905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.
    Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes.
    Kitabgi P
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):764-76. PubMed ID: 12630297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotensin, schizophrenia, and antipsychotic drug action.
    Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Biol Psychiatry; 2001 Dec; 50(11):856-72. PubMed ID: 11743941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
    Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
    Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins.
    Griebel G
    Curr Pharm Des; 2015; 21(26):3807-12. PubMed ID: 26044977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological and design issues in clinical trials of new neuroleptics: an overview.
    Awad AG
    Br J Psychiatry Suppl; 1993 Dec; (22):51-7. PubMed ID: 7906524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.
    Rao NP; Remington G
    Expert Opin Investig Drugs; 2013 Jul; 22(7):881-94. PubMed ID: 23639138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.